RSV Incidence Peaking In Pediatric Population, Vaccine Prevents Severe Disease
Respiratory syncytial virus is the leading cause of hospitalization among U.S. infants. A vaccine, nirsevimab, can reduce the ...
Hosted on MSN4h
Which Respiratory Virus Do I Have?
So, which respiratory virus invaded your cells? Several types of viruses could be the culprit: respiratory syncytial virus ...
infectiousdiseaseadvisor.com7h
RSVPreF Vaccine Is Safe, Effective in Adults Aged 18 to 59 at Severe Risk for RSV
The RSVPreF vaccine is safe and demonstrates immunobridging to efficacy among adults aged 18 to 59 who are at high risk for ...
McKnight's Long-Term Care News21h
Study: RSV vaccine may be more effective at protecting healthier older adults
The respiratory syncytial virus (RSV) vaccine may not protect older adults who are immunocompromised as much as their healthier peers, according to new research.
NC has high levels of RSV in wastewater, CDC says: What to do if you contract RSV
NC was one of 18 states with "high" or "very high" levels in wastewater, according to CDC monitoring. Here's what to know ...
Survey shows rising trust in RSV vaccines, steady views on others
Vaccines to protect against respiratory syncytial virus (RSV) in newborns and older adults are being more widely accepted by ...
The Tribune-Democrat1d
RSV cases rising in Pa., doctors urge caution for infants, seniors
Flu cases are surging across the commonwealth but for the youngest Pennsylvanians, another potentially dangerous respiratory virus is spreading quickly.
Pharmaceutical Technology3d
COVID-19 (S Protein) by Vaxart for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
COVID-19 (S Protein) is under clinical development by Vaxart and currently in Phase II for Coronavirus Disease 2019 (COVID-19).
Pharmaceutical Technology4d
ASC-60 by Sagimet Biosciences for Solid Tumor: Likelihood of Approval
ASC-60 is under clinical development by Sagimet Biosciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate ...